Comparisons of the effect of electrical stimulation methods on postmortem pH decline in beef muscle.

Results of four electrical stimulation (ES) studies were summarized to demonstrate the impact of different ES parameters on pH decline patterns in postmortem M. longissimus thoracis et lumborum. Postmortem pH decline was modeled as a non-linear function of time, and estimates of minimum obtainable pH, pH decline rates, and time to reach pH 6·0 were compared for each study. The decline model for study 4 (AC, 60 Hz, 50 V; 5 min post mortem) had a larger (P < 0·05) estimate for decline rate than that for study 1 (AC, 60 Hz, 400 V; 1 h post mortem) and the control (non-stimulated) data. The model estimate of time to pH 6·0 (0·56 h) for study 4 was the shortest (P < 0·05) for all treatments. Different ES parameters produce different pH decline patterns post mortem and, therefore, may impact product quality and fabrication and chilling protocols adopted in fresh beef processing.

Psychosocial implications of lung cancer.

Patients with lung cancer who are encouraged and permitted to verbalize their feelings by a staff that is interested, empathetic, and nonjudgmental are better able to overcome feelings of anxiety and fear, and they progress through the stages of the grieving process more easily. Communications between the lung cancer patient and the multidisciplinary staff should occur freely and without restraint. Unrealistic expectations made of the patient who is struggling to cope will almost certainly increase anxiety. Interventions must address coping responses of the patient and family living with lung cancer. Caregivers working with patients whose diagnoses are not favorable must examine their own feelings regarding terminal disease states and death before the entire cancer experience can be discussed openly and comfortably by the patient, family members, and health care team. The focus of care for families and patients living with lung cancer should be on care rather than cure.

Incidence of thrombocytopenia and serious hemorrhage among patients with solid tumors.

To evaluate the incidence of thrombocytopenia and bleeding among patients with solid tumors treated intensively with chemotherapy, the records of 1274 patients treated between 1972 and 1980 on protocols known to produce significant myelosuppression were reviewed. Three hundred one patients with solid tumors (breast, lung, melanoma, sarcoma, primary brain, testicular, hypernephroma and others) experienced 5063 days of thrombocytopenia (platelet count less than 50,000/microliters) and 670 days of severe thrombocytopenia (platelet count less than 20,000/microliters). The median number of days thrombocytopenia was 6 (range, 1-250). There were only 44 episodes of clinically detectable serious bleeding, primarily gastrointestinal (26/44), during thrombocytopenia and all but seven episodes first occurred at platelet counts between 20,000-50,000/microliters. Fifteen of the 44 bleeding episodes were associated with coagulation abnormalities, 24 occurred during serious infection, and 12 occurred at sites of tumors. One hundred forty-seven of the 301 patients (49%) received platelet transfusions. In 86 thrombocytopenic patients with central nervous system (CNS) tumors, there was no evidence of CNS bleeding during thrombocytopenia. Hemorrhagic deaths were uncommon, and of the 12 patients who died of bleeding, 7 had normal counts. There is a very low incidence of significant thrombocytopenia or bleeding among patients with solid tumors treated with combination chemotherapy or experimental agents escalated to maximally tolerated doses. These data suggest that with respect to thrombocytopenic bleeding intensive treatment of patients with solid tumors can be pursued with relative safety utilizing the standard transfusion supportive measures now widely available.